Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
10612studies shown
Showing 7,525-7,536 of 10,612
Drug study icon
CompletedNCT01710709

Effectiveness of intramuscular Formulation of Aripiprazole in Bipolarity

This study is completed in the United States, in France, in Canada, .... It is testing intramuscular Formulation of Aripiprazole for Bipolarity.

In United States
BipolarityDrugFrom 18 Years to 65 Years
Countries
United States, France, Canada, ...
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Bipolarity
Drug study icon
CompletedNCT02896296

Treatment Extension Study

This study is completed in the United States. It focuses on Addiction.

In United States
AddictionDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Indivior Inc.
Condition
Addiction
Drug study icon
CompletedNCT00421954

Ziprasidone Study for Psychosis Treatment in Adolescents

This study is completed in the United States. It focuses on Schizophrenia.

In United States
Schizophrenia, Depression, ...DrugFrom 13 Years to 17 Years
Countries
United States
Sponsor
New York State Psychiatric Institute
Condition
Schizophrenia, Depression, ...
Drug study icon
CompletedNCT01416064

Extension Study to 810P202

This study is completed in the United States. It focuses on ADHD.

In United States
ADHDDrugFrom 6 Years to 12 Years
Countries
United States
Sponsor
Supernus Pharmaceuticals, Inc.
Condition
ADHD
Drug study icon
CompletedNCT04578756

Cariprazine for schizophrenia

This study is completed in the United States. It is testing cariprazine for schizophrenia.

In United States
Bipolarity, SchizophreniaDrugFrom 5 Years to 17 Years
Countries
United States
Sponsor
AbbVie
Condition
Bipolarity, Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.